Results

Total Results: 948 records

Showing results for "developed".

221. Final Recommendation Statement: Perinatal Depression: Preventive Interventions | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/RecommendationStatementFinal/perinatal-depression-preventive-interventions
     February 12, 2019 - vs 50%, respectively; P = 0.02). 55 One woman taking nortriptyline and 1 woman taking sertraline developed

222. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the USPSTF (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/-TsBkyewVoFpC7htRmzWJa
     September 03, 2019 - Two investigators independently applied criteria developed by the USPSTF12 to rate the quality of each … first-degree or second-degree relatives with breast cancer (permits entry from age 40 years if both developed … age 50 years; permits entry at age 35 years if both relatives are first-degree and both relatives developed … atypical hyperplasia (permits entry from age 40 years); nulliparous and a first-degree relative who developed … for 288 mutation carriers who developed breast cancer during the trial.115 Of the 8 women with breast

223. Nominate a Recommendation Statement Topic | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/public-comments-and-nominations/nominate-recommendation-statement-topic
     April 01, 2019 - Nominate a Recommendation Statement Topic Share to Facebook Share to X Share to WhatsApp Share to Email Print Anyone - including individuals and organizations - can nominate a topic for the U.S. Preventive Services Task Force (USPSTF) to cons…

224. Archived: Evidence Summary: Breast Cancer: Medications for Risk Reduction | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/breast-cancer-medications-for-risk-reduction-2002
     May 06, 2002 - Using USPSTF methodology, we first developed … This risk was calculated by applying a multivariate logistic regression model developed by Gail et al … This study was developed by the RTI-UNC Evidence-based Practice Center under contract to the Agency for … , we rated the internal and external validity for each article in the evidence table using criteria developed

225. Archived: Evidence Summary: Lipid Disorders in Adults (Cholesterol, Dyslipidemia): Screening, 2001 | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/lipid-disorders-in-adults-cholesterol-dyslipidemia-screening-2001
     April 09, 2001 - costs in 1995. 4 Epidemiology Lipid disorders are common in the United States and other Western, developed … practice-based screening for lipid disorders in adults without known cardiovascular disease, we first developed … therapy do not appear to be increased. 70 However, formulas to calculate CHD risk 7 , 32 have been developed … Information This study was developed

226. Recommendation: Perinatal Depression: Preventive Interventions | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/recommendation/perinatal-depression-preventive-interventions
     February 12, 2019 - vs 50%, respectively; P = 0.02). 55 One woman taking nortriptyline and 1 woman taking sertraline developed

227. Celebrating 40 years of Prevention Guidance (pdf file)
     www.uspreventiveservicestaskforce.org/uspstf/sites/default/files/2024-06/USPSTF-40th-anniversary-timeline_0.pdf
     January 01, 2024 - Celebrating 40 years of Prevention Guidance Celebrating 40 years of Prevention Guidance For 40 years, the U.S. Preventive Services Task Force (USPSTF or Task Force) has improved the health of people nationwide by making evidence-based recommendations on preventive services. Clinicians, healthcare professionals…

228. James Stevermer, M.D., M.S.P.H. | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/about-uspstf/current-members/james-stevermer-md-msph
     January 01, 2021 - Share to Facebook Share to X Share to WhatsApp Share to Email Print James Stevermer, M.D., M.S.P.H. Member James Stevermer, M.D., M.S.P.H., is vice chair for academic affairs and the Paul Revare, M.D., professor of family and community medi…

229. Primary Care–Relevant Interventions to Prevent Opioid Use Disorder: Current Research and Evidence Gaps (pdf file)
     www.uspreventiveservicestaskforce.org/uspstf/sites/default/files/inline-files/prevention-of-opioid-user-disorder-ehc-tech-brief.pdf
     May 14, 2021 - Most of these more intense interventions are similar continuing medical education programs—some developed … Risk Assessment Multiple risk assessment tools have been developed to help identify patients who … and Opioid Assessment for Patients with Pain-Revised [SOAPP- R], Opioid Risk Tool [ORT]) have been developed … Models have also been developed to predict the risk of respiratory depression or overdose among individuals … for acute pain indications, recommend indications for which new evidence-based guidelines should be developed

230. Final Research Plan: Obstructive Sleep Apnea in Adults: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan/obstructive-sleep-apnea-in-adults-screening
     March 04, 2021 - Share to Facebook Share to X Share to WhatsApp Share to Email Print Final Research Plan Obstructive Sleep Apnea in Adults: Screening March 04, 2021 Recommendations made by the USPSTF are independent of the U.S. government. They should not be …

231. 11th Annual Report to Congress on High-Priority Evidence Gaps for Clinical Preventive Services (pdf file)
     www.uspreventiveservicestaskforce.org/uspstf/sites/default/files/inline-files/2021-uspstf-annual-report-to-congress.pdf
     January 01, 2021 - These organizations and agencies provide input on the recommendations as they are being developed and

232. Testimony for the House Energy and Commerce Health Subcommittee Hearing (pdf file)
     www.uspreventiveservicestaskforce.org/uspstf/sites/default/files/inline-files/tfcongresstestimony%20(3).pdf
     November 30, 2016 - Since its inception, the USPSTF has developed recommendations to inform care and to be useful guides … This paragraph was developed in consultation with Dr.

233. Archived: Final Research Plan: Obstructive Sleep Apnea in Adults: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan142/obstructive-sleep-apnea-in-adults-screening-january-2017
     October 30, 2014 - screened vs. nonscreened groups KQ 2: Prospective cohort studies and cross-sectional studies that developed

234. Research Gaps for Screening Breast Cancer: Evidence Gaps Research Taxonomy Table (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/QTkyWhfQHqFUy4He2B6HU4
     The research developed will be reviewed according to standard USPSTF criteria for inclusion in its evidence

235. Final Research Plan: Folic Acid Supplementation to Prevent Neural Tube Defects: Preventive Medication | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan/folic-acid-for-the-prevention-of-neural-tube-defects-preventive-medication
     October 21, 2021 - Share to Facebook Share to X Share to WhatsApp Share to Email Print Final Research Plan Folic Acid Supplementation to Prevent Neural Tube Defects: Preventive Medication October 21, 2021 Recommendations made by the USPSTF are independent of th…

236. Draft Research Plan: Cervical Cancer: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/draft-research-plan/cervical-cancer-screening-adults-adolescents
     October 28, 2021 - Share to Facebook Share to X Share to WhatsApp Share to Email Print in progress Draft Research Plan Cervical Cancer: Screening October 28, 2021 Recommendations made by the USPSTF are independent of the U.S. government. They should not be co…

237. Archived: Gestational Diabetes Mellitus: Screening, 2003 | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/recommendation/gestational-diabetes-mellitus-screening-2003
     February 01, 2003 - Diagnostic criteria in the United States are based on a 100‐g 3‐h OGTT, but these criteria were originally developed

238. Archived: Evidence Summary: Diabetes Mellitus (Type 2) in Adults: Screening, 2003 | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/diabetes-mellitus-type-2-in-adults-screening-2003
     February 03, 2003 - example, myocardial infarction [MI], stroke, heart failure, or sudden death), fewer than 5% will have developed … blindness, and fewer than 2% will have developed ESRD or had lower-extremity amputation. 10 Three … that represent five key questions in a logical chain between screening and health outcomes. 23 We developed … intermediate outcomes may herald future clinical benefits, few people in any group in these trials developed … We critically appraised each study using criteria developed by the USPSTF Methods Work Group.

239. Archived: Evidence Summary: Latent Tuberculosis Infection: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary-latent-tuberculosis/latent-tuberculosis-infection-screening-september-2016
     September 06, 2016 - immunocompetent individuals with a positive TST result will develop active TB disease in their lifetime. 4 In developed … investigators assessed the quality of each study as good, fair, or poor, using predefined criteria developed … After 5 years, 1.4% of the placebo group and 0.5% of the 24-week treatment group developed active TB, … For this subset, active TB developed in 5 individuals in the combination-therapy group and 10 individuals … b Quality assessed using criteria developed by the US Preventive Services Task Force.

240. Evidence Summary: Prevention of Dental Caries in Children Younger Than 5 Years: Screening and Interventions | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-summary/prevention-of-dental-caries-in-children-younger-than-age-5-years-screening-and-interventions1
     December 07, 2021 - independent investigators assessed the quality of each study as good, fair, or poor using predefined criteria developed